Aardvark Therapeutics Inc(AARD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:41 PM ET (Korea 10/31 08:41)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.21 | Insider Own | 41.42% | Shs Outstand | 21.9M | Perf Week | -2.16% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 23.46% | Insider Trans | -0.84% | Shs Float | 12.8M | Perf Month | -74.19% |
| Enterprise Value | -0.04B | PEG | - | EPS next Q | -0.72 | Inst Own | 25.21% | Short Float | 4.32% | Perf Quarter | -80.79% |
| Income | -0.07B | P/S | - | EPS this Y | -5.15% | Inst Trans | -6.94% | Short Ratio | 0.95 | Perf Half Y | -75.09% |
| Sales | 0.00B | P/B | 0.4 | EPS next 5Y | 8.96% | ROA | -61.06% | Short Interest | 0.55M | Perf YTD | -89.64% |
| Book/sh | 3.42 | P/C | 0.4 | EPS past 3/5Y | -60.85% - | ROE | -66.02% | 52W High | -91.81% ($16.60) | Perf Year | -87% |
| Cash/sh | 3.38 | P/FCF | - | Sales past 3/5Y | - | ROIC | -93.09% | 52W Low | 46.24% ($0.93) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -89.45% | Gross Margin | - | Volatility(W/M) | 48.08% 19.85% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.53 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.63 | EPS Q/Q | 0.56% | Profit Margin | - | RSI (14) | 24.88 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.63 | Sales Q/Q | - | SMA20 | -60.45% ($3.44) | Beta | 3.94 | Target Price | $7.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/11 | SMA50 | -71.51% ($4.77) | Rel Volume | 0.79 | Prev Close | $1.44 |
| Employees | 40 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 24.52% - | SMA200 | -78.48% ($6.32) | Avg Volume(3M) | 0.58M | Price | $1.36 |
| IPO | 2025/2/13 | Option/Short | Yes/Yes | Trades | 1293 | Volume | 458,419 | Change | -5.56% |
🧬 Aardvark Therapeutics is a US-based clinical-stage biopharmaceutical company developing oral small-molecule drugs that regulate feelings of fullness. The company focuses on a mechanism that suppresses appetite and overeating through bitter taste receptor (TAS2R) agonists, with the rare disease Prader-Willi syndrome and metabolic disorders serving as its primary therapeutic targets.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded less than usual. That is 79% of its average volume.
AARD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -5.2% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 25.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #446 of 595 in the industry
Based on market cap of $30M.
EYPT#444 EyePoint Inc $30M PER - 
ALGS#445 Aligos Therapeutics Inc $30M PER - AARD#446 Aardvark Therapeutics Inc $30M PER - 
PMN#447 ProMIS Neurosciences Inc $30M PER - 
MGX#448 Metagenomi Therapeutics Inc $29M PER - 
FAQ
What kind of company is AARD?
AARD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AARD?
The market cap of AARD is approximately $30M, ranking 5,070 within its sector.
What is the 52-week high and low for AARD?
AARD has recorded a 52-week high of $16.60 and a low of $0.93.
